Acquisition Signifies Increased Biopharma Provisions for the APAC Region

Leading Australian biopharmaceutical CDMO, AcuraBio (formerly Luina Bio), has been acquired by biotech investor Dr Glenn Haifer and Ampersand Capital Partners, a global healthcare private equity firm.

With over two decades of experience, AcuraBio is a globally focussed organisation bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries. AcuraBio provides recombinant proteins and vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics. 

The rebranding of the company signifies an innovative new growth phase for AcuraBio. As part of the transaction, Dr Haifer and Ampersand are bringing significant investment to the company, with a focus on expanding the organisation to better serve customers. To fuel additional growth, AcuraBio is planning to increase production facility capacity, and is actively evaluating expansion into new service offerings and technological capabilities. 

"We are very excited to be reinventing a company with such deep scientific experience," said Dr Haifer. "With our deep expertise and commitment to further investment, AcuraBio will be a leader in the APAC region for international biopharma clients attracted by the technology, scientific excellence, and innovation we will bring to the platform. I am excited to leverage Ampersand's industry expertise as we take AcuraBio to the next level." 

David Anderson, General Partner at Ampersand, said: "AcuraBio is strategically positioned in Australia to support international biopharma drug development. Australia has a strong reputation for clinical and scientific excellence which is the foundation to success for a company like AcuraBio. We are extremely pleased to be working with Dr Haifer, who is a proven biotech investor and growth strategist with a real focus on client-centric service innovations."

More information online